Br J Ophthalmol 96:i doi:10.1136/bjophthalmol-2012-301586
  • At a glance

Highlights from this issue

  1. Arun D Singh, Editors-in-Chief

Bevacizumab for Coats' disease

Ramasubramanian and Shields evaluated the effect of supplemental intravitreal bevacizumab in management of eight patients with Coats' disease manifesting total or partial exudative retinal detachment. Retinal telangiectasia were treated with laser photocoagulation and/or cryotherapy plus additional intravitreal bevacizumab (1.25 mg/0.05 ml). After a mean follow-up of 8.5 months, resolution of retinopathy (100%), subretinal fluid (100%) and retinal exudation (75%) was noted. However, vitreous fibrosis developed in four eyes that evolved into traction retinal detachment (three eyes). Such fibrotic reaction is not observed in Coats' disease treated without bevacizumab. The authors advise caution in the use of bevacizumab for Coats' disease. (see page 356)

A novel procedure for canalicular obstruction

Chen et al evaluated a new procedure for treating canalicular obstruction by re-canaliculisation and bicanalicular intubation (RC-BCI) in 30 adults (32 eyes) with canalicular obstruction. Silicone tubes were left in place for 2–3 months and were removed when patients had relief from epiphora. At a mean …

This article has not yet been cited by other articles.

Relevant Articles

Register for free content

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article